These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 39052709)

  • 21. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection.
    Callegaro A; Borleri D; Farina C; Napolitano G; Valenti D; Rizzi M; Maggiolo F
    J Med Virol; 2021 Jul; 93(7):4612-4615. PubMed ID: 33788281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
    Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
    Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine.
    Banga Ndzouboukou JL; Zhang YD; Lei Q; Lin XS; Yao ZJ; Fu H; Yuan LY; Fan XL
    Curr Med Sci; 2021 Dec; 41(6):1081-1086. PubMed ID: 34741251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.
    Ghione P; Gu JJ; Attwood K; Torka P; Goel S; Sundaram S; Mavis C; Johnson M; Thomas R; McWhite K; Darrall A; DeMarco J; Kostrewa J; Mohr A; Rivas L; Neiders M; Suresh L; Segal BH; Griffiths EA; Ramsperger V; Shen L; Hernandez-Ilizaliturri FJ
    Blood; 2021 Sep; 138(9):811-814. PubMed ID: 34189565
    [No Abstract]   [Full Text] [Related]  

  • 26. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.
    Haydu JE; Maron JS; Redd RA; Gallagher KME; Fischinger S; Barnes JA; Hochberg EP; Johnson PC; Takvorian RW; Katsis K; Portman D; Ruiters J; Sechio S; Devlin M; Regan C; Blumenthal KG; Banerji A; Judd AD; Scorsune KJ; McGree BM; Sherburne MM; Lynch JM; Weitzman JI; Lei M; Kotton CN; Dighe AS; Maus MV; Alter G; Abramson JS; Soumerai JD
    Blood Adv; 2022 Mar; 6(6):1671-1683. PubMed ID: 35073571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia.
    Parry H; McIlroy G; Bruton R; Damery S; Tyson G; Logan N; Davis C; Willett B; Zuo J; Ali M; Kaur M; Stephens C; Brant D; Otter A; McSkeane T; Rolfe H; Faustini S; Richter A; Lee S; Wandroo F; Shafeek S; Pratt G; Paneesha S; Moss P
    J Hematol Oncol; 2022 Jan; 15(1):3. PubMed ID: 35000597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the induction of humoral and cellular immunity by third vaccination for SARS-CoV-2.
    Murayama G; Kusaoi M; Horiuchi Y; Tabe Y; Naito T; Ito S; Yamaji K; Tamura N
    J Infect Chemother; 2024 Oct; 30(10):1021-1027. PubMed ID: 38570139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.
    Serwanga J; Oluka GK; Baine C; Ankunda V; Sembera J; Kato L; Katende JS; Odoch G; Auma BO; Gombe B; ; Musenero M; Kaleebu P
    PLoS One; 2024; 19(7):e0303113. PubMed ID: 39074077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19 mRNA Vaccination in Lactation: Assessment of Adverse Events and Vaccine Related Antibodies in Mother-Infant Dyads.
    Golan Y; Prahl M; Cassidy AG; Gay C; Wu AHB; Jigmeddagva U; Lin CY; Gonzalez VJ; Basilio E; Chidboy MA; Warrier L; Buarpung S; Li L; Murtha AP; Asiodu IV; Ahituv N; Flaherman VJ; Gaw SL
    Front Immunol; 2021; 12():777103. PubMed ID: 34804068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
    Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
    Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and immunological outcomes of SARS-CoV-2-infected vaccine responders, vaccine non-responders, and unvaccinated patients evaluated for neutralizing monoclonal antibody treatment at a single German tertiary care center: a retrospective cohort study with prospective follow-up.
    Triebelhorn J; Schneider J; Spinner CD; Iakoubov R; Voit F; Wagner L; Erber J; Rothe K; Berthele A; Pernpeintner V; Strauß EM; Renders L; Willmann A; Minic M; Vogel E; Christa C; Hoffmann D; Protzer U; Jeske SD
    Infection; 2024 Jun; 52(3):1143-1151. PubMed ID: 38305828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters.
    Magliulo D; Wade SD; Kyttaris VC
    Clin Immunol; 2022 Jan; 234():108897. PubMed ID: 34848357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.
    Parry H; McIlroy G; Bruton R; Ali M; Stephens C; Damery S; Otter A; McSkeane T; Rolfe H; Faustini S; Wall N; Hillmen P; Pratt G; Paneesha S; Zuo J; Richter A; Moss P
    Blood Cancer J; 2021 Jul; 11(7):136. PubMed ID: 34330895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
    Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
    Front Immunol; 2021; 12():786554. PubMed ID: 35003104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.
    Arroyo-Sánchez D; Cabrera-Marante O; Laguna-Goya R; Almendro-Vázquez P; Carretero O; Gil-Etayo FJ; Suàrez-Fernández P; Pérez-Romero P; Rodríguez de Frías E; Serrano A; Allende LM; Pleguezuelo D; Paz-Artal E
    J Clin Immunol; 2022 Feb; 42(2):240-252. PubMed ID: 34787773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Anti-SARS-CoV-2-Specific Antibody Signatures in Maternal and Infant Blood after COVID-19 Infection versus COVID-19 Vaccination during Pregnancy.
    Sabharwal V; Taglauer E; Demos R; Snyder-Cappione J; Shaik-Dasthagirisaheb YB; Parker-Kelleher S; Hunnewell J; Boateng J; Clarke K; Yuen R; Barnett ED; Wachman EM; Yarrington CD
    Am J Perinatol; 2024 May; 41(S 01):e2970-e2977. PubMed ID: 37774748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study.
    Hillyer A; Quint A; Ghassemian A; Joh-Carnella N; Knauer MJ; Dawd D; Lazo-Langner A; Mangel J; Lam S; Abdoh H; Xenocostas A; Deotare U; Saini L; Foster C; Louzada M; Ho J; Chin-Yee I; Phua CW
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):305-315. PubMed ID: 38336492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
    Goodyear CS; Patel A; Barnes E; Willicombe M; Siebert S; de Silva TI; Snowden JA; Lim SH; Bowden SJ; Billingham L; Richter A; Carroll M; Carr EJ; Beale R; Rea D; Parry H; Pirrie S; Lim Z; Satsangi J; Dunachie SJ; Cook G; Miller P; Basu N; Gilmour A; Hodgkins AM; Evans L; Hughes A; Longet S; Meacham G; Yong KL; A'Hearne MJ; Koh MBC; Burns SO; Orchard K; Paterson C; McIlroy G; Murray SM; Thomson T; Dimitriadis S; Goulston L; Miller S; Keillor V; Prendecki M; Thomas D; Kirkham A; McInnes IB; Kearns P;
    Lancet Rheumatol; 2024 Jun; 6(6):e339-e351. PubMed ID: 38734019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.